Fairvalue-Calculator Fairvalue-Calculator
EN DE

Novanta Inc (NOVT) Fair Value & Analysis

Technology · US · Market cap $5.6B

Price$151.34
Fair Value$33.70
Upside-77.7%
Quality95/100
Evidence: High Range $21.79 – $49.82

Analysis

Novanta Inc (NOVT) currently trades at $151.34, while our model-based Fair Value estimate is $33.70 — implying the stock looks roughly 77.7% overvalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and in…

Open the full interactive analysis →

Similar stocks

Keyence Corporation (KYCCF) -50% Keysight Technologies, Inc (KEYS) -73% Garmin Ltd (GRMN) -31% Chroma ATE Inc (2360) -88% Teledyne Technologies Incorporated (TDY) -37% Hexagon AB (HXGBF) -35%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.